These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 1283793

  • 1. Vitronectin modulates glycosaminoglycan dependent reactions of protein C inhibitor.
    Seiffert D, Geiger M, Ecke S, Binder BR.
    Thromb Haemost; 1992 Dec 07; 68(6):657-61. PubMed ID: 1283793
    [Abstract] [Full Text] [Related]

  • 2. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
    España F, Estellés A, Fernández PJ, Gilabert J, Sánchez-Cuenca J, Griffin JH.
    Thromb Haemost; 1993 Dec 20; 70(6):989-94. PubMed ID: 8165623
    [Abstract] [Full Text] [Related]

  • 3. Limited proteolysis of vitronectin by plasmin destroys heparin binding activity.
    Sane DC, Moser TL, Greenberg CS.
    Thromb Haemost; 1991 Sep 02; 66(3):310-4. PubMed ID: 1720904
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion.
    Elia C, Cassol E, Sidenius N, Blasi F, Castagna A, Poli G, Alfano M.
    J Leukoc Biol; 2007 Nov 02; 82(5):1212-20. PubMed ID: 17704294
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein.
    Ecke S, Geiger M, Resch I, Jerabek I, Sting L, Maier M, Binder BR.
    J Biol Chem; 1992 Apr 05; 267(10):7048-52. PubMed ID: 1313031
    [Abstract] [Full Text] [Related]

  • 6. Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma.
    España F, Estelles A, Griffin JH, Aznar J.
    Thromb Haemost; 1991 Jan 23; 65(1):46-51. PubMed ID: 1850876
    [Abstract] [Full Text] [Related]

  • 7. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
    Whitley BR, Church FC.
    Int J Oncol; 2005 Sep 23; 27(3):749-57. PubMed ID: 16077925
    [Abstract] [Full Text] [Related]

  • 8. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
    Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT.
    Exp Cell Res; 1996 May 01; 224(2):344-53. PubMed ID: 8612711
    [Abstract] [Full Text] [Related]

  • 9. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
    Liu Y, Stack SM, Lakka SS, Khan AJ, Woodley DT, Rao JS, Rao CN.
    Arch Biochem Biophys; 1999 Oct 01; 370(1):112-8. PubMed ID: 10496984
    [Abstract] [Full Text] [Related]

  • 10. Heparin stimulation of the inhibition of activated protein C and other enzymes by human protein C inhibitor--influence of the molecular weightof heparin and ionic strength.
    Aznar J, España F, Estellés A, Royo M.
    Thromb Haemost; 1996 Dec 01; 76(6):983-8. PubMed ID: 8972021
    [Abstract] [Full Text] [Related]

  • 11. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
    Kanse SM, Chavakis T, Al-Fakhri N, Hersemeyer K, Monard D, Preissner KT.
    J Cell Sci; 2004 Jan 26; 117(Pt 3):477-85. PubMed ID: 14679304
    [Abstract] [Full Text] [Related]

  • 12. Heparin binding of protein-C inhibitor--analysis of the effect of heparin on the interaction of protein-C inhibitor with tissue kallikrein.
    Ecke S, Geiger M, Binder BR.
    Eur J Biochem; 1997 Sep 01; 248(2):475-80. PubMed ID: 9346305
    [Abstract] [Full Text] [Related]

  • 13. Protein C and its inhibitor in malignancy.
    Suzuki K, Hayashi T.
    Semin Thromb Hemost; 2007 Oct 01; 33(7):667-72. PubMed ID: 18000793
    [Abstract] [Full Text] [Related]

  • 14. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
    Schroeck F, Arroyo de Prada N, Sperl S, Schmitt M, Viktor M.
    Biol Chem; 2002 Oct 01; 383(7-8):1143-9. PubMed ID: 12437099
    [Abstract] [Full Text] [Related]

  • 15. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard.
    España F, Sanchez-Cuenca J, Vera CD, Estelles A, Gilabert J.
    J Lab Clin Med; 1993 Dec 01; 122(6):711-9. PubMed ID: 7504042
    [Abstract] [Full Text] [Related]

  • 16. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R, Biliran H, Sager R, Sheng S.
    Cancer Res; 2000 Sep 01; 60(17):4771-8. PubMed ID: 10987285
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
    van Meijer M, Stoop A, Smilde A, Preissner KT, van Zonneveld AJ, Pannekoek H.
    Thromb Haemost; 1997 Mar 01; 77(3):516-21. PubMed ID: 9066004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.